-
Table 1 shows the baseline characteristics of the study population. Approximately 15.2%, 27.9%, 30.8%, 19.1%, and 7.0% of the participants had 0-1, 2, 3, 4, and 5-6 ideal CVH metrics, respectively. Of the total population, 62.4% were women, and the mean age was 57.8 ± 9.4 years. The mean age decreased and the proportions of women and participants with ≥ 9 years of education increased with increasing numbers of ideal CVH metrics.
Table 1. Characteristics of the Study Population at Baseline
Variables Total Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Number of participants (%) 8, 395 (100) 1, 275 (15.2) 2, 342 (27.9) 2, 583 (30.8) 1, 607 (19.1) 588 (7.0) Age (years) 57.8 ± 9.4 58.7 ± 8.9 59.0 ± 9.2 58.1 ± 9.1 56.7 ± 10.2 52.9 ± 8.7 < 0.0001 Women, n (%) 5, 236 (62.4) 501 (39.3) 1, 379 (58.9) 1, 704 (66.0) 1, 172 (72.9) 480 (81.6) < 0.0001 ≥ 9 years of education, n (%) 5, 497 (65.7) 805 (63.4) 1, 443 (61.8) 1, 630 (63.4) 1, 131 (70.5) 488 (83.1) < 0.0001 Current drinkers, n (%) 863 (10.6) 247 (19.7) 253 (11.1) 230 (9.2) 108 (6.9) 25 (4.4) < 0.0001 Physical activity (METs-h/wk) 23.1 (0.0-102.3) 23.1 (0.0-92.4) 23.1 (0.0-69.3) 23.1 (0.0-92.4) 40.0 (0.0-132.0) 51.1 (0.0-153.6) < 0.0001 BMI (kg/m2) 25.1 ± 3.2 27.4 ± 2.6 26.3 ± 3.0 24.5 ± 3.0 23.2 ± 2.5 22.3 ± 2.0 < 0.0001 Systolic BP (mmHg) 140.4 ± 19.8 147.4 ± 18.5 145.9 ± 18.2 141.2 ± 18.2 133.2 ± 19.1 119.1 ± 16.5 < 0.0001 Diastolic BP (mmHg) 82.8 ± 10.3 86.6 ± 10.0 85.2 ± 9.7 83.0 ± 9.6 79.3 ± 9.9 73.3 ± 8.6 < 0.0001 Total cholesterol (mg/dL) 206.3 ± 39.2 229.5 ± 39.7 216.9 ± 37.7 202.3 ± 37.5 188.9 ± 32.2 178.3 ± 23.2 < 0.0001 Triglyceride (mg/dL) 103.0 (72.9-146.6) 133.8 (98.5-192.5) 116.5 (83.5-162.4) 98.5 (71.4-136.1) 85.0 (63.2-117.3) 72.6 (54.9-101.5) < 0.0001 LDL-c (mg/dL) 123.1 ± 33.1 140.0 ± 31.5 131.6 ± 32.9 120.1 ± 32.3 109.9 ± 28.5 101.3 ± 21.4 < 0.0001 HDL-c (mg/dL) 51.4 ± 12.3 49.2 ± 11.7 51.0 ± 12.2 52.0 ± 13.2 52.2 ± 11.7 52.9 ± 10.9 < 0.0001 FPG (mg/dL) 99.5 ± 26.6 120.4 ± 36.9 103.4 ± 28.9 94.5 ± 19.4 89.8 ± 14.0 86.5 ± 7.1 < 0.0001 2hPG (mg/dL) 146.4 ± 75.7 196.2 ± 99.8 158.0 ± 82.6 135.3 ± 62.2 121.1 ± 45.8 110.6 ± 29.5 < 0.0001 Hypertension, n (%) 6, 520 (77.7) 1, 200 (94.1) 2, 120 (90.5) 2, 093 (81.0) 980 (61.0) 127 (21.6) < 0.0001 Diabetes, n (%) 1, 415 (16.9) 542 (42.5) 512 (21.9) 274 (10.6) 76 (4.7) 11 (1.9) < 0.0001 Dyslipidemia, n (%) 3, 299 (39.3) 961 (75.4) 1, 630 (69.6) 1, 494 (57.8) 639 (39.8) 86 (14.6) < 0.0001 Subclinical atherosclerosis measures CIMT (mm) 0.58 ± 0.11 0.62 ± 0.12 0.60 ± 0.11 0.58 ± 0.10 0.56 ± 0.10 0.53 ± 0.08 < 0.0001 baPWV (cm/s) 1598.2 ± 363.3 1681.0 ± 353.4 1660.5 ± 355.8 1603.5 ± 370.2 1520.3 ± 350.2 1359.8 ± 262.1 < 0.0001 UACR (mg/g) 4.80 (2.77-8.85) 5.18 (2.84-10.40) 5.02 (2.90-9.67) 4.77 (2.67-8.73) 4.61 (2.68-8.22) 4.19 (2.77-7.15) < 0.0001 Note. CVH, cardiovascular health; MET-h/wk, metabolic equivalent hours per week; BMI, body-mass index; BP, blood pressure; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; FPG, fasting plasma glucose; 2hPG, 2-hour post-load glucose; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity; UACR, urinary albumin-to-creatinine ratio. All continuous variables were expressed as mean ± SD or medians (interquartile ranges). In the cross-sectional analysis of the total 8, 395 participants at baseline, the prevalence of different atherosclerosis measures is presented in Figure 2. The prevalence rates of carotid plaques, increased CIMT, increased baPWV, and microalbuminuria at baseline were found to decrease with better CVH status (all P values for trend < 0.0001). Similar findings were obtained in the subgroup analysis (Supplementary Tables S1-S4 available in www. besjournal.com), when the study population was stratified by sex or age (< 60 years or ≥ 60 years). Remarkably, participants with 5-6 ideal CVH metrics still had 4.8%, 5.4%, 7.7%, and 2.6% prevalence rates of carotid plaques, increased CIMT, increased baPWV, and microalbuminuria, respectively.
Figure 2. Prevalence of different measures of subclinical atherosclerosis according to numbers of ideal CVH metrics at baseline. P values for trend were adjusted for age and sex. CVH, cardiovascular health.
Table Supplementary Table S1. Prevalence of Different Measures of Subclinical Atherosclerosis in Middle-aged Participants (40-60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 301/5, 201 75/735 97/1, 351 83/1, 574 38/1, 065 8/476 < 0.0001 (%) (5.8) (10.2) (7.2) (5.3) (3.6) (1.7) Increased CIMT Cases/participants 577/5, 201 169/735 198/1, 351 135/1, 574 62/1, 065 13/476 < 0.0001 (%) (11.1) (23.0) (14.7) (8.6) (5.8) (2.7) Increased baPWV Cases/participants 625/5, 201 149/735 225/1, 351 173/1, 574 67/1, 065 11/476 < 0.0001 (%) (12.0) (20.3) (16.7) (11.0) (6.3) (2.3) Microalbuminuria Cases/participants 245/5, 201 46/735 81/1, 351 64/1, 574 44/1, 065 10/476 < 0.0001 (%) (4.7) (6.3) (6.0) (4.1) (4.1) (2.1) Table Supplementary Table S2. Prevalence of Different Measures of Subclinical Atherosclerosis in Elderly Participants (≥ 60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 849/3, 194 160/540 270/991 271/1, 009 128/542 20/112 0.0046 (%) (26.6) (29.6) (27.3) (26.9) (23.6) (17.9) Increased CIMT Cases/participants 1114/3, 194 228/540 379/991 327/1, 009 161/542 19/112 < 0.0001 (%) (34.9) (42.2) (38.2) (32.4) (29.7) (17.0) Increased baPWV Cases/participants 1470/3, 194 282/540 490/991 451/1, 009 213/542 34/112 < 0.0001 (%) (46.0) (52.2) (49.5) (44.7) (39.3) (30.4) Microalbuminuria Cases/participants 216/3, 194 46/540 78/991 68/1, 009 19/542 5/112 0.0005 (%) (6.8) (8.5) (7.9) (6.7) (3.5) (4.5) Table Supplementary Table S3. Prevalence of Different Measures of Subclinical Atherosclerosis in Male Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 550/3, 159 154/774 172/963 141/879 74/435 9/108 0.0063 (%) (17.4) (19.9) (17.9) (16.0) (17.0) (8.3) Increased CIMT Cases/participants 952/3, 159 285/774 311/963 224/879 118/435 14/108 < 0.0001 (%) (30.1) (36.8) (32.3) (25.5) (27.1) (13.0) Increased baPWV Cases/participants 767/3, 159 221/774 247/963 204/879 85/435 10/108 < 0.0001 (%) (24.3) (28.6) (25.7) (23.2) (19.5) (9.3) Microalbuminuria Cases/participants 128/3, 159 42/774 45/963 29/879 10/435 2/108 0.0012 (%) (4.1) (5.4) (4.7) (3.3) (2.3) (1.9) Table Supplementary Table S4. Prevalence of Different Measures of Subclinical Atherosclerosis in Female Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 600/5, 236 81/501 195/1, 379 213/1, 704 92/1, 172 19/480 < 0.0001 (%) (11.5) (16.2) (14.1) (12.5) (7.9) (4.0) Increased CIMT Cases/participants 739/5, 236 112/501 266/1, 379 238/1, 704 105/1, 172 18/480 < 0.0001 (%) (14.1) (22.4) (19.3) (14.0) (9.0) (3.8) Increased baPWV Cases/participants 1328/5, 236 210/501 468/1, 379 420/1, 704 195/1, 172 35/480 < 0.0001 (%) (25.4) (41.9) (33.9) (24.7) (16.6) (7.3) Microalbuminuria Cases/participants 333/5, 236 50/501 114/1, 379 103/1, 704 53/1, 172 13/480 < 0.0001 (%) (6.4) (10.0) (8.3) (6.0) (4.5) (2.3) After a median 4.3-year follow-up period, a total of 571 (13.2%) among 4, 313 participants without carotid plaques at baseline had developed new plaques. In addition, 214 (4.65%) among 4, 602 participants with normal UACR at baseline had developed microalbuminuria. The incidence rates of carotid plaques and microalbuminuria were found to decrease significantly with increasing numbers of ideal CVH metrics (both P values for trend < 0.01, Figure 3). The development of increased CIMT or increased baPWV defined as the highest quartile among participants at follow-up was also found to decrease significantly (both P values for trend < 0.01, Figure 3).
Figure 3. Incidence of different measures of subclinical atherosclerosis at follow-up according to numbers of ideal CVH metrics at baseline. P values for trend were adjusted for age and sex. CVH, cardiovascular health.
As shown in Table 2, the numbers of ideal CVH metrics at baseline were inversely associated with CIMT levels at follow-up, after adjustment for baseline CIMT levels and other covariates, including age, sex, drinking status, and education. A similar decreasing trend was found for measurements of baPWV and UACR at follow-up, when the numbers of ideal CVH metrics at baseline increased. Taking participants with 0-1 ideal CVH metric as reference, participants with 2, 3, 4, and 5-6 ideal CVH metrics were found to have 19%, 20%, 34%, and 54% decreased risk of developing carotid plaques, respectively, after adjustment for age, sex, drinking status, and education level (P value for trend = 0.0016, Table 3). The corresponding proportions were 16%, 24%, 22%, and 43% for increased CIMT; 29%, 36%, 49%, and 74% for increased baPWV; and 15%, 36%, 43%, and 58% for microalbuminuria. The inverse association remained significant after further adjustment for baseline levels of CIMT and UACR in the respective analyses (both P values for trend < 0.05, Table 3), whereas it was borderline significant for baPWV after adjustment for baseline baPWV levels (P for trend = 0.0568).
Table 2. The Association of Numbers of Ideal CVH Metrics at Baseline with Subclinical Atherosclerosis Measures at Follow-up in Linear Regression Analysis
Measures of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 β (SE) 3 β (SE) 4 β (SE) 5-6 β (SE) Model 1 CIMT 0 (ref) -0.020 (0.007) -0.028 (0.007) -0.030 (0.008) -0.059 (0.010) < 0.0001 baPWV 0 (ref) -0.310 (0.132) -0.502 (0.129) -0.843 (0.138) -2.146 (0.179) < 0.0001 Log (UACR) 0 (ref) -0.021 (0.020) -0.053 (0.019) -0.047 (0.021) -0.074 (0.029) 0.0012 Model 2 CIMT 0 (ref) -0.014 (0.007) -0.020 (0.007) -0.016 (0.007) -0.037 (0.010) 0.0016 baPWV 0 (ref) -0.372 (0.121) -0.535 (0.119) -0.785 (0.129) -1.667 (0.167) < 0.0001 Log (UACR) 0 (ref) -0.049 (0.019) -0.086 (0.019) -0.078 (0.021) -0.079 (0.029) 0.0001 Model 3 CIMT 0 (ref) -0.014 (0.007) -0.019 (0.007) -0.014 (0.008) -0.035 (0.010) 0.0049 baPWV 0 (ref) -0.306 (0.098) -0.170 (0.097) -0.213 (0.105) -0.460 (0.138) 0.0505 Log (UACR) 0 (ref) -0.032 (0.018) -0.058 (0.018) -0.049 (0.020) -0.048 (0.028) 0.0124 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of CIMT at follow-up), baseline baPWV (for analysis of baPWV at follow-up), and baseline UACR (for analysis of UACR at follow-up) based on model 2. β values are regression coefficients. UACR was log10-transformed in linear regression analysis. CVH, cardiovascular health; SE, standard error; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity; UACR, urinary albumin-to-creatinine ratio. Table 3. Risks of Developing Subclinical Atherosclerosis at Follow-up in Association with Numbers of Ideal CVH Metrics at Baseline
Incidence of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend P for Interaction* P for Interaction** 0-1 2 OR (95% CI) 3 OR (95% CI) 4 OR (95% CI) 5-6 OR (95% CI) Model 1 Carotid plaque 1 (ref) 0.77 (0.59-0.99) 0.71 (0.55-0.92) 0.54 (0.40-0.73) 0.29 (0.18-0.49) < 0.0001 - - Increased CIMT 1 (ref) 0.79 (0.63-0.98) 0.69 (0.56-0.86) 0.66 (0.52-0.84) 0.44 (0.32-0.61) < 0.0001 - - Increased baPWV 1 (ref) 0.77 (0.61-0.96) 0.68 (0.54-0.85) 0.54 (0.42-0.70) 0.20 (0.13-0.31) < 0.0001 - - Microalbuminuria 1 (ref) 0.97 (0.65-1.44) 0.73 (0.49-1.10) 0.65 (0.41-1.04) 0.38 (0.17-0.87) 0.0024 - - Model 2 Carotid plaque 1 (ref) 0.81 (0.62-1.06) 0.80 (0.61-1.05) 0.66 (0.48-0.91) 0.46 (0.27-0.79) 0.0016 0.2209 0.7406 Increased CIMT 1 (ref) 0.84 (0.67-1.05) 0.76 (0.61-0.95) 0.78 (0.61-0.99) 0.57 (0.41-0.81) 0.0020 0.0326 0.9836 Increased baPWV 1 (ref) 0.71 (0.56-0.91) 0.64 (0.50-0.82) 0.51 (0.38-0.67) 0.26 (0.16-0.41) < 0.0001 < 0.0001 0.0823 Microalbuminuria 1 (ref) 0.85 (0.57-1.28) 0.64 (0.42-0.98) 0.57 (0.35-0.93) 0.42 (0.18-0.95) 0.0020 0.7880 0.4624 Model 3 Increased CIMT 1 (ref) 0.85 (0.68-1.06) 0.77 (0.62-0.96) 0.80 (0.63-1.03) 0.60 (0.42-0.84) 0.0060 0.0424 0.9947 Increased baPWV 1 (ref) 0.67 (0.51-0.89) 0.79 (0.60-1.04) 0.68 (0.50-0.93) 0.57 (0.34-0.97) 0.0568 0.0041 0.5361 Microalbuminuria 1 (ref) 0.94 (0.62-1.43) 0.74 (0.48-1.13) 0.68 (0.41-1.12) 0.49 (0.21-1.14) 0.0195 0.8011 0.5561 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of increased CIMT at follow-up), baseline baPWV (for analysis of increased baPWV at follow-up), and baseline UACR (for analysis of microalbuminuria at follow-up) based on model 2. CVH, cardiovascular health; OR, odds ratio; CI, confidence interval; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity. *Interactions between age at baseline (continuous variable) and numbers of ideal CVH metrics (0-1, 2, 3, 4, or 5-6) on subclinical atherosclerosis. **Interactions between sex (male or female) and numbers of ideal CVH metrics (0-1, 2, 3, 4, or 5-6) on subclinical atherosclerosis. The prevalence and the incidence of different measures of subclinical atherosclerosis according to the numbers of ideal CVH metrics at baseline in the subgroups of age (40-60 vs. ≥ 60 years) and sex (men vs. women) are shown in Supplementary Tables S1-S8 (available in www.besjournal.com). Significant interactions of age and CVH were found on CIMT and baPWV progression (Table 3).
Table Supplementary Table S5. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Middle-aged Participants (40-60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 254/2, 969 56/397 71/801 77/912 42/604 8/255 < 0.0001 (%) (8.6) (14.1) (8.9) (8.4) (7.0) (3.1) Increased CIMT cases/participants 755/2, 811 127/336 213/741 229/886 140/596 46/252 < 0.0001 (%) (26.9) (37.8) (28.7) (25.9) (23.5) (18.3) Increased baPWV cases/participants 493/2, 773 100/356 147/716 162/859 70/590 14/252 < 0.0001 (%) (17.8) (28.1) (20.5) (18.9) (11.9) (5.6) Microalbuminuria cases/participants 102/3, 007 18/420 33/815 28/925 19/595 4/252 0.0431 (%) (3.4) (4.3) (4.0) (3.0) (3.2) (1.6) Table Supplementary Table S6. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Elderly Participants (≥ 60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 313/1, 344 55/228 101/412 102/430 45/227 10/47 0.2582 (%) (23.3) (24.1) (24.5) (23.7) (19.8) (21.3) Increased CIMT cases/participants 460/1, 177 70/187 135/341 147/388 91/213 17/48 0.6290 (%) (39.1) (37.4) (39.6) (37.9) (42.7) (35.4) Increased baPWV cases/participants 442/975 71/157 129/281 134/312 96/188 12/37 0.9981 (%) (45.3) (45.2) (45.9) (43.0) (51.1) (32.4) Microalbuminuria cases/participants 112/1, 595 22/276 40/493 33/501 14/271 3/54 0.1125 (%) (7.0) (8.0) (8.1) (6.6) (5.2) (5.6) Table Supplementary Table S7. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Male Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 263/1, 519 68/378 91/475 72/422 27/195 5/49 0.0855 (%) (17.3) (18.0) (19.2) (17.1) (13.9) (10.2) Increased CIMT cases/participants 464/1, 278 119/296 137/381 131/378 64/176 13/47 0.1150 (%) (36.2) (40.2) (36.0) (34.7) (36.4) (27.7) Increased baPWV cases/participants 369/1, 380 104/344 106/413 98/387 56/189 5/47 0.1067 (%) (26.7) (30.2) (25.7) (25.3) (29.6) (10.6) Microalbuminuria cases/participants 59/1, 712 20/442 20/530 15/473 3/215 1/52 0.0353 (%) (3.5) (4.5) (3.8) (3.2) (1.4) (1.9) Table Supplementary Table S8. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Female Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 304/2, 794 43/247 81/738 107/920 60/636 13/253 < 0.0001 (%) (10.9) (17.4) (11.0) (11.6) (9.4) (5.1) Increased CIMT cases/participants 751/2, 710 78/227 211/701 245/896 167/633 50/252 0.0002 (%) (27.7) (34.4) (30.1) (27.3) (26.4) (19.8) Increased baPWV cases/participants 566/2, 368 67/169 170/584 198/784 110/589 21/242 < 0.0001 (%) (23.9) (39.6) (29.1) (25.3) (18.7) (8.7) Microalbuminuria cases/participants 155/2, 890 20/254 53/778 46/953 30/651 6/254 0.0008 (%) (5.4) (7.9) (6.8) (4.8) (4.6) (2.4) We also examined the association between ideal CVH metrics and newly developed MACEs. A total of 385 participants had developed fatal or nonfatal myocardial infarction or stroke during the follow-up, including 2.94% of those with 5-6 ideal CVH metrics and 6.82% of those with 0-1 ideal CVH metrics at baseline (Supplementary Table S9 available in www. besjournal.com). Results of the Cox regression analysis, taking participants with 0-1 ideal CVH metrics as reference, showed that participants with 2, 3, 4, and 5-6 ideal metrics had a lower risk for MACEs, and the hazard ratios (95% CI) were 1.00 (0.76-1.33), 0.71 (0.53-0.96), 0.66 (0.49-0.93), and 0.43 (0.24-0.76), respectively, in the unadjusted model, with P for trend < 0.0001 (Supplementary Table S9). In the adjusted model of age, sex, drinking status, and education, the dose-response association was found to be still significant (P for trend = 0.0019).
Table Supplementary Table S9. Risks of Developing MACEs During Follow-up in Association with Numbers of Ideal CVH Metrics at Baseline
Model Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 HR (95% CI) 3 HR (95% CI) 4 HR (95% CI) 5-6 HR (95% CI) Cases/participants (%) 74/1, 085 (6.82) 135/2, 011 (6.71) 104/2, 180 (4.77) 58/1, 326 (4.37) 14/476 (2.94) Model 1 1 (ref) 1.00 (0.76-1.33) 0.71 (0.53-0.96) 0.66 (0.49-0.93) 0.43 (0.24-0.76) < 0.0001 Model 2 1 (ref) 0.95 (0.71-1.26) 0.71 (0.52-0.96) 0.68 (0.48-0.96) 0.60 (0.33-1.07) 0.0019 Model 3 1 (ref) 1.11 (0.83-1.49) 0.95 (0.68-1.33) 1.02 (0.68-1.53) 1.01 (0.54-1.90) 0.7734 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for systolic blood pressure, blood glucose and body mass index based on model 2. MACEs, major adverse cardiovascular events; CVH, cardiovascular health; HR, hazard ratio; CI, confidence interval. BP, blood glucose level, and BMI are key factors for the development of atherosclerosis and MACEs. Although they were included in the concept of CVH, we took them into further adjustment model to test sensitivity. As shown in Supplementary Table S9 (in model 3), the association between ideal CVH and MACEs was attenuated after further adjustment of systolic BP, blood glucose level, and BMI. However, the associations of ideal CVH with the progression of CIMT and UACR were still significant in the linear regression analysis (P for trend = 0.0092 and 0.0460, respectively, Supplementary Table S10 available in www.besjournal.com) and also with the development of carotid plaques and increased CIMT in the logistic regression analysis (P for trend = 0.0166 and 0.0377, respectively, Supplementary Table S11 available in www.besjournal.com).
Table Supplementary Table S10. The Association of Numbers of Ideal CVH Metrics at Baseline with Subclinical Atherosclerosis Measures at Follow-up in Linear Regression Analysis
Measures of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 β (SE) 3 β (SE) 4 β (SE) 5-6 β (SE) Model 1 CIMT 0 (ref) -0.020 (0.007) -0.028 (0.007) -0.030 (0.008) -0.059 (0.010) < 0.0001 baPWV 0 (ref) -0.310 (0.132) -0.502 (0.129) -0.843 (0.138) -2.146 (0.179) < 0.0001 logUACR 0 (ref) -0.021 (0.020) -0.053 (0.019) -0.047 (0.021) -0.074 (0.029) 0.0012 Model 2 CIMT 0 (ref) -0.014 (0.007) -0.020 (0.007) -0.016 (0.007) -0.037 (0.010) 0.0016 baPWV 0 (ref) -0.372 (0.121) -0.535 (0.119) -0.785 (0.129) -1.667 (0.167) < 0.0001 logUACR 0 (ref) -0.049 (0.019) -0.086 (0.019) -0.078 (0.021) -0.079 (0.029) 0.0001 Model 3 CIMT 0 (ref) -0.014 (0.007) -0.019 (0.007) -0.014 (0.008) -0.035 (0.010) 0.0049 baPWV 0 (ref) -0.306 (0.098) -0.170 (0.097) -0.213 (0.105) -0.460(0.138) 0.0505 logUACR 0 (ref) -0.032 (0.018) -0.058 (0.018) -0.049 (0.020) -0.048 (0.028) 0.0124 Model 4 CIMT 0 (ref) -0.016 (0.007) -0.022 (0.008) -0.018 (0.009) -0.038 (0.001) 0.0092 baPWV 0 (ref) -0.201 (0.102) -0.009 (0.108) -0.007 (0.124) -0.188 (0.159) 0.7285 logUACR 0 (ref) -0.005 (0.019) -0.016 (0.020) -0.010 (0.024) -0.025 (0.032) 0.0460 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of CIMT at follow-up), baseline baPWV (for analysis of baPWV at follow-up), and baseline UACR (for analysis of UACR at follow-up) based on model 2. Model 4 was further adjusted for systolic blood pressure, blood glucose and body mass index based on mode 3. β values are regression coefficients. UACR was log10-transformed in linear regression analysis. CVH, cardiovascular health; SE, standard error; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity; UACR, urinary albumin-to-creatinine ratio. Table Supplementary Table S11. Risks of Developing Subclinical Atherosclerosis at Follow-up in Association with Numbers of Ideal CVH metrics at Baseline
Incidence of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend P for Interaction* P for Interaction** 0-1 2 OR (95% CI) 3 OR (95% CI) 4 OR (95% CI) 5-6 OR (95% CI) Model 1 Carotid plaque 1 (ref) 0.77 (0.59-0.99) 0.71 (0.55-0.92) 0.54 (0.40-0.73) 0.29 (0.18-0.49) < 0.0001 - - Increased CIMT 1 (ref) 0.79 (0.63-0.98) 0.69 (0.56-0.86) 0.66 (0.52-0.84) 0.44 (0.32-0.61) < 0.0001 - - Increased baPWV 1 (ref) 0.77 (0.61-0.96) 0.68 (0.54-0.85) 0.54 (0.42-0.70) 0.20 (0.13-0.31) < 0.0001 - - Microalbuminuria 1 (ref) 0.97 (0.65-1.44) 0.73 (0.49-1.10) 0.65 (0.41-1.04) 0.38 (0.17-0.87) 0.0024 - - Model 2 Carotid plaque 1 (ref) 0.81 (0.62-1.06) 0.80 (0.61-1.05) 0.66 (0.48-0.91) 0.46 (0.27-0.79) 0.0016 0.2209 0.7406 Increased CIMT 1 (ref) 0.84 (0.67-1.05) 0.76 (0.61-0.95) 0.78 (0.61-0.99) 0.57 (0.41-0.81) 0.0020 0.0326 0.9836 Increased baPWV 1 (ref) 0.71 (0.56-0.91) 0.64 (0.50-0.82) 0.51 (0.38-0.67) 0.26 (0.16-0.41) < 0.0001 < 0.0001 0.0823 Microalbuminuria 1 (ref) 0.85 (0.57-1.28) 0.64 (0.42-0.98) 0.57 (0.35-0.93) 0.42 (0.18-0.95) 0.0020 0.7880 0.4624 Model 3 Increased CIMT 1 (ref) 0.85 (0.68-1.06) 0.77 (0.62-0.96) 0.80 (0.63-1.03) 0.60 (0.42-0.84) 0.0060 0.0424 0.9947 Increased baPWV 1 (ref) 0.67 (0.51-0.89) 0.79 (0.60-1.04) 0.68 (0.50-0.93) 0.57 (0.34-0.97) 0.0568 0.0041 0.5361 Microalbuminuria 1 (ref) 0.94 (0.62-1.43) 0.74 (0.48-1.13) 0.68 (0.41-1.12) 0.49 (0.21-1.14) 0.0195 0.8011 0.5561 Model 4 Carotid plaque 1 (ref) 0.83 (0.62-1.09) 0.81 (0.60-1.09) 0.68 (0.47-0.99) 0.49 (0.28-0.89) 0.0166 0.2922 0.7080 Increased CIMT 1 (ref) 0.84 (0.67-1.06) 0.77 (0.60-0.99) 0.81 (0.61-1.08) 0.61 (0.42-0.90) 0.0377 0.0465 0.9521 Increased baPWV 1 (ref) 0.72 (0.54-0.96) 0.84 (0.61-1.15) 0.73 (0.50-1.05) 0.62 (0.35-1.09) 0.2014 0.0061 0.4898 Microalbuminuria 1 (ref) 1.28 (0.82-1.98) 1.26 (0.77-2.05) 1.44 (0.80-2.62) 1.21 (0.48-3.08) 0.3786 0.8479 0.3450 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of increased CIMT at follow-up), baseline baPWV (for analysis of increased baPWV at follow-up), and baseline UACR (for analysis of microalbuminuria at follow-up) based on model 2. Model 4 was further adjusted for systolic blood pressure, blood glucose and body mass index based on model 3. CVH, cardiovascular health; OR, odds ratio; CI, confidence interval; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity. *Interactions between age at baseline (continuous variable) and numbers of ideal CVH metrics (0-1, 2, 3, 4 or 5-6) on subclinical atherosclerosis. ** Interactions between sex (male or female) and numbers of ideal CVH metrics (0-1, 2, 3, 4 or 5-6) on subclinical atherosclerosis.
doi: 10.3967/bes2019.036
Ideal Cardiovascular Health is Inversely Associated with Subclinical Atherosclerosis: A Prospective Analysis
-
Abstract:
Objective Ideal cardiovascular health (CVH) could predict a lower risk of developing cardiovascular diseases. This study was conducted to investigate the association between ideal CVH and subclinical atherosclerosis in a population cohort of Chinese adults aged ≥ 40 years. Methods This study was designed as a cross-sectional analysis of 8, 395 participants who had complete data at baseline and a prospective analysis of 4, 879 participants who had complete data at 4.3 years of follow-up. Ideal CVH metrics were defined according to the American Heart Association. Subclinical atherosclerosis was evaluated by plaques in carotid arteries, carotid intima-media thickness (CIMT), brachial-ankle pulse wave velocity (baPWV), and urinary albumin-to-creatinine ratio (UACR). Results Both the prevalence and incidence of atherosclerosis measures were found to be decreased with increasing numbers of ideal CVH metrics at baseline (all P values for trend < 0.01). The levels of CIMT and UACR at follow-up showed an inverse and significant association with the numbers of ideal CVH metrics at baseline (both P values for trend < 0.05) but a borderline significant association with baPWV (P for trend=0.0505). Taking participants with 0-1 ideal metric as reference, we found that participants with 5-6 ideal metrics had significantly lower risks of developing carotid plaques (odds ratio, OR=0.46; 95% confidence interval, CI 0.27-0.79), increased CIMT (OR=0.60; 95% CI 0.42-0.84), and increased baPWV (OR=0.57; 95% CI 0.34-0.97) after full adjustments. A significant interactive effect of age and CVH was detected on CIMT and baPWV progression (both P values for interaction < 0.05). Conclusion The numbers of ideal CVH metrics showed a significant and inverse association with the risk of developing subclinical atherosclerosis in middle-aged and elderly Chinese adults, whereas its dose-response effect was attenuated in individuals aged ≥ 60 years and partially weakened in male participants. -
Key words:
- Cardiovascular health /
- Subclinical atherosclerosis /
- Cohort
-
Table 1. Characteristics of the Study Population at Baseline
Variables Total Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Number of participants (%) 8, 395 (100) 1, 275 (15.2) 2, 342 (27.9) 2, 583 (30.8) 1, 607 (19.1) 588 (7.0) Age (years) 57.8 ± 9.4 58.7 ± 8.9 59.0 ± 9.2 58.1 ± 9.1 56.7 ± 10.2 52.9 ± 8.7 < 0.0001 Women, n (%) 5, 236 (62.4) 501 (39.3) 1, 379 (58.9) 1, 704 (66.0) 1, 172 (72.9) 480 (81.6) < 0.0001 ≥ 9 years of education, n (%) 5, 497 (65.7) 805 (63.4) 1, 443 (61.8) 1, 630 (63.4) 1, 131 (70.5) 488 (83.1) < 0.0001 Current drinkers, n (%) 863 (10.6) 247 (19.7) 253 (11.1) 230 (9.2) 108 (6.9) 25 (4.4) < 0.0001 Physical activity (METs-h/wk) 23.1 (0.0-102.3) 23.1 (0.0-92.4) 23.1 (0.0-69.3) 23.1 (0.0-92.4) 40.0 (0.0-132.0) 51.1 (0.0-153.6) < 0.0001 BMI (kg/m2) 25.1 ± 3.2 27.4 ± 2.6 26.3 ± 3.0 24.5 ± 3.0 23.2 ± 2.5 22.3 ± 2.0 < 0.0001 Systolic BP (mmHg) 140.4 ± 19.8 147.4 ± 18.5 145.9 ± 18.2 141.2 ± 18.2 133.2 ± 19.1 119.1 ± 16.5 < 0.0001 Diastolic BP (mmHg) 82.8 ± 10.3 86.6 ± 10.0 85.2 ± 9.7 83.0 ± 9.6 79.3 ± 9.9 73.3 ± 8.6 < 0.0001 Total cholesterol (mg/dL) 206.3 ± 39.2 229.5 ± 39.7 216.9 ± 37.7 202.3 ± 37.5 188.9 ± 32.2 178.3 ± 23.2 < 0.0001 Triglyceride (mg/dL) 103.0 (72.9-146.6) 133.8 (98.5-192.5) 116.5 (83.5-162.4) 98.5 (71.4-136.1) 85.0 (63.2-117.3) 72.6 (54.9-101.5) < 0.0001 LDL-c (mg/dL) 123.1 ± 33.1 140.0 ± 31.5 131.6 ± 32.9 120.1 ± 32.3 109.9 ± 28.5 101.3 ± 21.4 < 0.0001 HDL-c (mg/dL) 51.4 ± 12.3 49.2 ± 11.7 51.0 ± 12.2 52.0 ± 13.2 52.2 ± 11.7 52.9 ± 10.9 < 0.0001 FPG (mg/dL) 99.5 ± 26.6 120.4 ± 36.9 103.4 ± 28.9 94.5 ± 19.4 89.8 ± 14.0 86.5 ± 7.1 < 0.0001 2hPG (mg/dL) 146.4 ± 75.7 196.2 ± 99.8 158.0 ± 82.6 135.3 ± 62.2 121.1 ± 45.8 110.6 ± 29.5 < 0.0001 Hypertension, n (%) 6, 520 (77.7) 1, 200 (94.1) 2, 120 (90.5) 2, 093 (81.0) 980 (61.0) 127 (21.6) < 0.0001 Diabetes, n (%) 1, 415 (16.9) 542 (42.5) 512 (21.9) 274 (10.6) 76 (4.7) 11 (1.9) < 0.0001 Dyslipidemia, n (%) 3, 299 (39.3) 961 (75.4) 1, 630 (69.6) 1, 494 (57.8) 639 (39.8) 86 (14.6) < 0.0001 Subclinical atherosclerosis measures CIMT (mm) 0.58 ± 0.11 0.62 ± 0.12 0.60 ± 0.11 0.58 ± 0.10 0.56 ± 0.10 0.53 ± 0.08 < 0.0001 baPWV (cm/s) 1598.2 ± 363.3 1681.0 ± 353.4 1660.5 ± 355.8 1603.5 ± 370.2 1520.3 ± 350.2 1359.8 ± 262.1 < 0.0001 UACR (mg/g) 4.80 (2.77-8.85) 5.18 (2.84-10.40) 5.02 (2.90-9.67) 4.77 (2.67-8.73) 4.61 (2.68-8.22) 4.19 (2.77-7.15) < 0.0001 Note. CVH, cardiovascular health; MET-h/wk, metabolic equivalent hours per week; BMI, body-mass index; BP, blood pressure; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; FPG, fasting plasma glucose; 2hPG, 2-hour post-load glucose; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity; UACR, urinary albumin-to-creatinine ratio. All continuous variables were expressed as mean ± SD or medians (interquartile ranges). Supplementary Table S1. Prevalence of Different Measures of Subclinical Atherosclerosis in Middle-aged Participants (40-60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 301/5, 201 75/735 97/1, 351 83/1, 574 38/1, 065 8/476 < 0.0001 (%) (5.8) (10.2) (7.2) (5.3) (3.6) (1.7) Increased CIMT Cases/participants 577/5, 201 169/735 198/1, 351 135/1, 574 62/1, 065 13/476 < 0.0001 (%) (11.1) (23.0) (14.7) (8.6) (5.8) (2.7) Increased baPWV Cases/participants 625/5, 201 149/735 225/1, 351 173/1, 574 67/1, 065 11/476 < 0.0001 (%) (12.0) (20.3) (16.7) (11.0) (6.3) (2.3) Microalbuminuria Cases/participants 245/5, 201 46/735 81/1, 351 64/1, 574 44/1, 065 10/476 < 0.0001 (%) (4.7) (6.3) (6.0) (4.1) (4.1) (2.1) Supplementary Table S2. Prevalence of Different Measures of Subclinical Atherosclerosis in Elderly Participants (≥ 60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 849/3, 194 160/540 270/991 271/1, 009 128/542 20/112 0.0046 (%) (26.6) (29.6) (27.3) (26.9) (23.6) (17.9) Increased CIMT Cases/participants 1114/3, 194 228/540 379/991 327/1, 009 161/542 19/112 < 0.0001 (%) (34.9) (42.2) (38.2) (32.4) (29.7) (17.0) Increased baPWV Cases/participants 1470/3, 194 282/540 490/991 451/1, 009 213/542 34/112 < 0.0001 (%) (46.0) (52.2) (49.5) (44.7) (39.3) (30.4) Microalbuminuria Cases/participants 216/3, 194 46/540 78/991 68/1, 009 19/542 5/112 0.0005 (%) (6.8) (8.5) (7.9) (6.7) (3.5) (4.5) Supplementary Table S3. Prevalence of Different Measures of Subclinical Atherosclerosis in Male Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 550/3, 159 154/774 172/963 141/879 74/435 9/108 0.0063 (%) (17.4) (19.9) (17.9) (16.0) (17.0) (8.3) Increased CIMT Cases/participants 952/3, 159 285/774 311/963 224/879 118/435 14/108 < 0.0001 (%) (30.1) (36.8) (32.3) (25.5) (27.1) (13.0) Increased baPWV Cases/participants 767/3, 159 221/774 247/963 204/879 85/435 10/108 < 0.0001 (%) (24.3) (28.6) (25.7) (23.2) (19.5) (9.3) Microalbuminuria Cases/participants 128/3, 159 42/774 45/963 29/879 10/435 2/108 0.0012 (%) (4.1) (5.4) (4.7) (3.3) (2.3) (1.9) Supplementary Table S4. Prevalence of Different Measures of Subclinical Atherosclerosis in Female Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Baseline Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques Cases/participants 600/5, 236 81/501 195/1, 379 213/1, 704 92/1, 172 19/480 < 0.0001 (%) (11.5) (16.2) (14.1) (12.5) (7.9) (4.0) Increased CIMT Cases/participants 739/5, 236 112/501 266/1, 379 238/1, 704 105/1, 172 18/480 < 0.0001 (%) (14.1) (22.4) (19.3) (14.0) (9.0) (3.8) Increased baPWV Cases/participants 1328/5, 236 210/501 468/1, 379 420/1, 704 195/1, 172 35/480 < 0.0001 (%) (25.4) (41.9) (33.9) (24.7) (16.6) (7.3) Microalbuminuria Cases/participants 333/5, 236 50/501 114/1, 379 103/1, 704 53/1, 172 13/480 < 0.0001 (%) (6.4) (10.0) (8.3) (6.0) (4.5) (2.3) Table 2. The Association of Numbers of Ideal CVH Metrics at Baseline with Subclinical Atherosclerosis Measures at Follow-up in Linear Regression Analysis
Measures of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 β (SE) 3 β (SE) 4 β (SE) 5-6 β (SE) Model 1 CIMT 0 (ref) -0.020 (0.007) -0.028 (0.007) -0.030 (0.008) -0.059 (0.010) < 0.0001 baPWV 0 (ref) -0.310 (0.132) -0.502 (0.129) -0.843 (0.138) -2.146 (0.179) < 0.0001 Log (UACR) 0 (ref) -0.021 (0.020) -0.053 (0.019) -0.047 (0.021) -0.074 (0.029) 0.0012 Model 2 CIMT 0 (ref) -0.014 (0.007) -0.020 (0.007) -0.016 (0.007) -0.037 (0.010) 0.0016 baPWV 0 (ref) -0.372 (0.121) -0.535 (0.119) -0.785 (0.129) -1.667 (0.167) < 0.0001 Log (UACR) 0 (ref) -0.049 (0.019) -0.086 (0.019) -0.078 (0.021) -0.079 (0.029) 0.0001 Model 3 CIMT 0 (ref) -0.014 (0.007) -0.019 (0.007) -0.014 (0.008) -0.035 (0.010) 0.0049 baPWV 0 (ref) -0.306 (0.098) -0.170 (0.097) -0.213 (0.105) -0.460 (0.138) 0.0505 Log (UACR) 0 (ref) -0.032 (0.018) -0.058 (0.018) -0.049 (0.020) -0.048 (0.028) 0.0124 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of CIMT at follow-up), baseline baPWV (for analysis of baPWV at follow-up), and baseline UACR (for analysis of UACR at follow-up) based on model 2. β values are regression coefficients. UACR was log10-transformed in linear regression analysis. CVH, cardiovascular health; SE, standard error; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity; UACR, urinary albumin-to-creatinine ratio. Table 3. Risks of Developing Subclinical Atherosclerosis at Follow-up in Association with Numbers of Ideal CVH Metrics at Baseline
Incidence of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend P for Interaction* P for Interaction** 0-1 2 OR (95% CI) 3 OR (95% CI) 4 OR (95% CI) 5-6 OR (95% CI) Model 1 Carotid plaque 1 (ref) 0.77 (0.59-0.99) 0.71 (0.55-0.92) 0.54 (0.40-0.73) 0.29 (0.18-0.49) < 0.0001 - - Increased CIMT 1 (ref) 0.79 (0.63-0.98) 0.69 (0.56-0.86) 0.66 (0.52-0.84) 0.44 (0.32-0.61) < 0.0001 - - Increased baPWV 1 (ref) 0.77 (0.61-0.96) 0.68 (0.54-0.85) 0.54 (0.42-0.70) 0.20 (0.13-0.31) < 0.0001 - - Microalbuminuria 1 (ref) 0.97 (0.65-1.44) 0.73 (0.49-1.10) 0.65 (0.41-1.04) 0.38 (0.17-0.87) 0.0024 - - Model 2 Carotid plaque 1 (ref) 0.81 (0.62-1.06) 0.80 (0.61-1.05) 0.66 (0.48-0.91) 0.46 (0.27-0.79) 0.0016 0.2209 0.7406 Increased CIMT 1 (ref) 0.84 (0.67-1.05) 0.76 (0.61-0.95) 0.78 (0.61-0.99) 0.57 (0.41-0.81) 0.0020 0.0326 0.9836 Increased baPWV 1 (ref) 0.71 (0.56-0.91) 0.64 (0.50-0.82) 0.51 (0.38-0.67) 0.26 (0.16-0.41) < 0.0001 < 0.0001 0.0823 Microalbuminuria 1 (ref) 0.85 (0.57-1.28) 0.64 (0.42-0.98) 0.57 (0.35-0.93) 0.42 (0.18-0.95) 0.0020 0.7880 0.4624 Model 3 Increased CIMT 1 (ref) 0.85 (0.68-1.06) 0.77 (0.62-0.96) 0.80 (0.63-1.03) 0.60 (0.42-0.84) 0.0060 0.0424 0.9947 Increased baPWV 1 (ref) 0.67 (0.51-0.89) 0.79 (0.60-1.04) 0.68 (0.50-0.93) 0.57 (0.34-0.97) 0.0568 0.0041 0.5361 Microalbuminuria 1 (ref) 0.94 (0.62-1.43) 0.74 (0.48-1.13) 0.68 (0.41-1.12) 0.49 (0.21-1.14) 0.0195 0.8011 0.5561 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of increased CIMT at follow-up), baseline baPWV (for analysis of increased baPWV at follow-up), and baseline UACR (for analysis of microalbuminuria at follow-up) based on model 2. CVH, cardiovascular health; OR, odds ratio; CI, confidence interval; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity. *Interactions between age at baseline (continuous variable) and numbers of ideal CVH metrics (0-1, 2, 3, 4, or 5-6) on subclinical atherosclerosis. **Interactions between sex (male or female) and numbers of ideal CVH metrics (0-1, 2, 3, 4, or 5-6) on subclinical atherosclerosis. Supplementary Table S5. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Middle-aged Participants (40-60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 254/2, 969 56/397 71/801 77/912 42/604 8/255 < 0.0001 (%) (8.6) (14.1) (8.9) (8.4) (7.0) (3.1) Increased CIMT cases/participants 755/2, 811 127/336 213/741 229/886 140/596 46/252 < 0.0001 (%) (26.9) (37.8) (28.7) (25.9) (23.5) (18.3) Increased baPWV cases/participants 493/2, 773 100/356 147/716 162/859 70/590 14/252 < 0.0001 (%) (17.8) (28.1) (20.5) (18.9) (11.9) (5.6) Microalbuminuria cases/participants 102/3, 007 18/420 33/815 28/925 19/595 4/252 0.0431 (%) (3.4) (4.3) (4.0) (3.0) (3.2) (1.6) Supplementary Table S6. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Elderly Participants (≥ 60 years) According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 313/1, 344 55/228 101/412 102/430 45/227 10/47 0.2582 (%) (23.3) (24.1) (24.5) (23.7) (19.8) (21.3) Increased CIMT cases/participants 460/1, 177 70/187 135/341 147/388 91/213 17/48 0.6290 (%) (39.1) (37.4) (39.6) (37.9) (42.7) (35.4) Increased baPWV cases/participants 442/975 71/157 129/281 134/312 96/188 12/37 0.9981 (%) (45.3) (45.2) (45.9) (43.0) (51.1) (32.4) Microalbuminuria cases/participants 112/1, 595 22/276 40/493 33/501 14/271 3/54 0.1125 (%) (7.0) (8.0) (8.1) (6.6) (5.2) (5.6) Supplementary Table S7. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Male Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 263/1, 519 68/378 91/475 72/422 27/195 5/49 0.0855 (%) (17.3) (18.0) (19.2) (17.1) (13.9) (10.2) Increased CIMT cases/participants 464/1, 278 119/296 137/381 131/378 64/176 13/47 0.1150 (%) (36.2) (40.2) (36.0) (34.7) (36.4) (27.7) Increased baPWV cases/participants 369/1, 380 104/344 106/413 98/387 56/189 5/47 0.1067 (%) (26.7) (30.2) (25.7) (25.3) (29.6) (10.6) Microalbuminuria cases/participants 59/1, 712 20/442 20/530 15/473 3/215 1/52 0.0353 (%) (3.5) (4.5) (3.8) (3.2) (1.4) (1.9) Supplementary Table S8. Incidence of Different Measures of Subclinical Atherosclerosis at Follow-up in Female Participants According to Numbers of Ideal CVH Metrics at Baseline
Measures of Subclinical Atherosclerosis at Follow-up Total Number of Ideal CVH Metrics at Baseline P for Trend 0-1 2 3 4 5-6 Carotid plaques cases/participants 304/2, 794 43/247 81/738 107/920 60/636 13/253 < 0.0001 (%) (10.9) (17.4) (11.0) (11.6) (9.4) (5.1) Increased CIMT cases/participants 751/2, 710 78/227 211/701 245/896 167/633 50/252 0.0002 (%) (27.7) (34.4) (30.1) (27.3) (26.4) (19.8) Increased baPWV cases/participants 566/2, 368 67/169 170/584 198/784 110/589 21/242 < 0.0001 (%) (23.9) (39.6) (29.1) (25.3) (18.7) (8.7) Microalbuminuria cases/participants 155/2, 890 20/254 53/778 46/953 30/651 6/254 0.0008 (%) (5.4) (7.9) (6.8) (4.8) (4.6) (2.4) Supplementary Table S9. Risks of Developing MACEs During Follow-up in Association with Numbers of Ideal CVH Metrics at Baseline
Model Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 HR (95% CI) 3 HR (95% CI) 4 HR (95% CI) 5-6 HR (95% CI) Cases/participants (%) 74/1, 085 (6.82) 135/2, 011 (6.71) 104/2, 180 (4.77) 58/1, 326 (4.37) 14/476 (2.94) Model 1 1 (ref) 1.00 (0.76-1.33) 0.71 (0.53-0.96) 0.66 (0.49-0.93) 0.43 (0.24-0.76) < 0.0001 Model 2 1 (ref) 0.95 (0.71-1.26) 0.71 (0.52-0.96) 0.68 (0.48-0.96) 0.60 (0.33-1.07) 0.0019 Model 3 1 (ref) 1.11 (0.83-1.49) 0.95 (0.68-1.33) 1.02 (0.68-1.53) 1.01 (0.54-1.90) 0.7734 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for systolic blood pressure, blood glucose and body mass index based on model 2. MACEs, major adverse cardiovascular events; CVH, cardiovascular health; HR, hazard ratio; CI, confidence interval. Supplementary Table S10. The Association of Numbers of Ideal CVH Metrics at Baseline with Subclinical Atherosclerosis Measures at Follow-up in Linear Regression Analysis
Measures of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend 0-1 2 β (SE) 3 β (SE) 4 β (SE) 5-6 β (SE) Model 1 CIMT 0 (ref) -0.020 (0.007) -0.028 (0.007) -0.030 (0.008) -0.059 (0.010) < 0.0001 baPWV 0 (ref) -0.310 (0.132) -0.502 (0.129) -0.843 (0.138) -2.146 (0.179) < 0.0001 logUACR 0 (ref) -0.021 (0.020) -0.053 (0.019) -0.047 (0.021) -0.074 (0.029) 0.0012 Model 2 CIMT 0 (ref) -0.014 (0.007) -0.020 (0.007) -0.016 (0.007) -0.037 (0.010) 0.0016 baPWV 0 (ref) -0.372 (0.121) -0.535 (0.119) -0.785 (0.129) -1.667 (0.167) < 0.0001 logUACR 0 (ref) -0.049 (0.019) -0.086 (0.019) -0.078 (0.021) -0.079 (0.029) 0.0001 Model 3 CIMT 0 (ref) -0.014 (0.007) -0.019 (0.007) -0.014 (0.008) -0.035 (0.010) 0.0049 baPWV 0 (ref) -0.306 (0.098) -0.170 (0.097) -0.213 (0.105) -0.460(0.138) 0.0505 logUACR 0 (ref) -0.032 (0.018) -0.058 (0.018) -0.049 (0.020) -0.048 (0.028) 0.0124 Model 4 CIMT 0 (ref) -0.016 (0.007) -0.022 (0.008) -0.018 (0.009) -0.038 (0.001) 0.0092 baPWV 0 (ref) -0.201 (0.102) -0.009 (0.108) -0.007 (0.124) -0.188 (0.159) 0.7285 logUACR 0 (ref) -0.005 (0.019) -0.016 (0.020) -0.010 (0.024) -0.025 (0.032) 0.0460 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of CIMT at follow-up), baseline baPWV (for analysis of baPWV at follow-up), and baseline UACR (for analysis of UACR at follow-up) based on model 2. Model 4 was further adjusted for systolic blood pressure, blood glucose and body mass index based on mode 3. β values are regression coefficients. UACR was log10-transformed in linear regression analysis. CVH, cardiovascular health; SE, standard error; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity; UACR, urinary albumin-to-creatinine ratio. Supplementary Table S11. Risks of Developing Subclinical Atherosclerosis at Follow-up in Association with Numbers of Ideal CVH metrics at Baseline
Incidence of Subclinical Atherosclerosis at Follow-up Numbers of Ideal CVH Metrics at Baseline P for Trend P for Interaction* P for Interaction** 0-1 2 OR (95% CI) 3 OR (95% CI) 4 OR (95% CI) 5-6 OR (95% CI) Model 1 Carotid plaque 1 (ref) 0.77 (0.59-0.99) 0.71 (0.55-0.92) 0.54 (0.40-0.73) 0.29 (0.18-0.49) < 0.0001 - - Increased CIMT 1 (ref) 0.79 (0.63-0.98) 0.69 (0.56-0.86) 0.66 (0.52-0.84) 0.44 (0.32-0.61) < 0.0001 - - Increased baPWV 1 (ref) 0.77 (0.61-0.96) 0.68 (0.54-0.85) 0.54 (0.42-0.70) 0.20 (0.13-0.31) < 0.0001 - - Microalbuminuria 1 (ref) 0.97 (0.65-1.44) 0.73 (0.49-1.10) 0.65 (0.41-1.04) 0.38 (0.17-0.87) 0.0024 - - Model 2 Carotid plaque 1 (ref) 0.81 (0.62-1.06) 0.80 (0.61-1.05) 0.66 (0.48-0.91) 0.46 (0.27-0.79) 0.0016 0.2209 0.7406 Increased CIMT 1 (ref) 0.84 (0.67-1.05) 0.76 (0.61-0.95) 0.78 (0.61-0.99) 0.57 (0.41-0.81) 0.0020 0.0326 0.9836 Increased baPWV 1 (ref) 0.71 (0.56-0.91) 0.64 (0.50-0.82) 0.51 (0.38-0.67) 0.26 (0.16-0.41) < 0.0001 < 0.0001 0.0823 Microalbuminuria 1 (ref) 0.85 (0.57-1.28) 0.64 (0.42-0.98) 0.57 (0.35-0.93) 0.42 (0.18-0.95) 0.0020 0.7880 0.4624 Model 3 Increased CIMT 1 (ref) 0.85 (0.68-1.06) 0.77 (0.62-0.96) 0.80 (0.63-1.03) 0.60 (0.42-0.84) 0.0060 0.0424 0.9947 Increased baPWV 1 (ref) 0.67 (0.51-0.89) 0.79 (0.60-1.04) 0.68 (0.50-0.93) 0.57 (0.34-0.97) 0.0568 0.0041 0.5361 Microalbuminuria 1 (ref) 0.94 (0.62-1.43) 0.74 (0.48-1.13) 0.68 (0.41-1.12) 0.49 (0.21-1.14) 0.0195 0.8011 0.5561 Model 4 Carotid plaque 1 (ref) 0.83 (0.62-1.09) 0.81 (0.60-1.09) 0.68 (0.47-0.99) 0.49 (0.28-0.89) 0.0166 0.2922 0.7080 Increased CIMT 1 (ref) 0.84 (0.67-1.06) 0.77 (0.60-0.99) 0.81 (0.61-1.08) 0.61 (0.42-0.90) 0.0377 0.0465 0.9521 Increased baPWV 1 (ref) 0.72 (0.54-0.96) 0.84 (0.61-1.15) 0.73 (0.50-1.05) 0.62 (0.35-1.09) 0.2014 0.0061 0.4898 Microalbuminuria 1 (ref) 1.28 (0.82-1.98) 1.26 (0.77-2.05) 1.44 (0.80-2.62) 1.21 (0.48-3.08) 0.3786 0.8479 0.3450 Note. Model 1 was unadjusted. Model 2 was adjusted for sex, age, drinking status, and education. Model 3 was further adjusted for baseline CIMT (for analysis of increased CIMT at follow-up), baseline baPWV (for analysis of increased baPWV at follow-up), and baseline UACR (for analysis of microalbuminuria at follow-up) based on model 2. Model 4 was further adjusted for systolic blood pressure, blood glucose and body mass index based on model 3. CVH, cardiovascular health; OR, odds ratio; CI, confidence interval; CIMT, carotid intima-media thickness; baPWV, brachial-ankle pulse wave velocity. *Interactions between age at baseline (continuous variable) and numbers of ideal CVH metrics (0-1, 2, 3, 4 or 5-6) on subclinical atherosclerosis. ** Interactions between sex (male or female) and numbers of ideal CVH metrics (0-1, 2, 3, 4 or 5-6) on subclinical atherosclerosis. -
[1] Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med, 2015; 372, 1333-41. doi: 10.1056/NEJMoa1406656 [2] Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010:the Global Burden of Disease 2010 study. Circulation, 2014; 129, 1493-501. doi: 10.1161/CIRCULATIONAHA.113.004046 [3] Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction:the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation, 2010; 121, 586-613. doi: 10.1161/CIRCULATIONAHA.109.192703 [4] Folsom AR, Yatsuya H, Nettleton JA, et al. Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence. J Am Coll Cardiol, 2011; 57, 1690-6. doi: 10.1016/j.jacc.2010.11.041 [5] Han C, Liu F, Yang X, et al. Ideal cardiovascular health and incidence of atherosclerotic cardiovascular disease among Chinese adults:the China-PAR project. Sci China Life Sci, 2018; 61, 504-14. doi: 10.1007/s11427-018-9281-6 [6] Polonsky TS, Ning H, Daviglus ML, et al. Association of Cardiovascular Health With Subclinical Disease and Incident Events:The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc, 2017; 6. http://cn.bing.com/academic/profile?id=ddd7078ac2411ff372a36f316a8ed5a2&encoded=0&v=paper_preview&mkt=zh-cn [7] Gaye B, Canonico M, Perier MC, et al. Ideal Cardiovascular Health, Mortality, and Vascular Events in Elderly Subjects:The Three-City Study. J Am Coll Cardiol, 2017; 69, 3015-26. doi: 10.1016/j.jacc.2017.05.011 [8] Muntner P, Judd SE, Gao L, et al. Cardiovascular risk factors in CKD associate with both ESRD and mortality. J Am Soc Nephrol, 2013; 24, 1159-65. doi: 10.1681/ASN.2012070642 [9] Fuster V, Lois F, Franco M. Early identification of atherosclerotic disease by noninvasive imaging. Nat Rev Cardiol, 2010; 7, 327-33. doi: 10.1038/nrcardio.2010.54 [10] Xanthakis V, Enserro DM, Murabito JM, et al. Ideal cardiovascular health:associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham Offspring Study. Circulation, 2014; 130, 1676-83. doi: 10.1161/CIRCULATIONAHA.114.009273 [11] Crichton GE, Elias MF, Robbins MA. Cardiovascular health and arterial stiffness:the Maine-Syracuse Longitudinal Study. J Hum Hypertens, 2014; 28, 444-9. doi: 10.1038/jhh.2013.131 [12] Gaye B, Mustafic H, Laurent S, et al. Ideal Cardiovascular Health and Subclinical Markers of Carotid Structure and Function:The Paris Prospective Study Ⅲ. Arterioscler Thromb Vasc Biol, 2016; 36, 2115-24. doi: 10.1161/ATVBAHA.116.307920 [13] Hao Z, Zhang Y, Li Y, et al. The Association between Ideal Cardiovascular Health Metrics and Extracranial Carotid Artery Stenosis in a Northern Chinese Population:A Cross-Sectional Study. Sci Rep, 2016; 6, 31720. doi: 10.1038/srep31720 [14] Wang YQ, Wang CF, Zhu L, et al. Ideal cardiovascular health and the subclinical impairments of cardiovascular diseases:a cross-sectional study in central south China. BMC Cardiovasc Disord, 2017; 17, 269. doi: 10.1186/s12872-017-0697-9 [15] Santos IS, Goulart AC, Pereira AC, et al. Association between Cardiovascular Health Score and Carotid Intima-Media Thickness:Cross-Sectional Analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) Baseline Assessment. J Am Soc Echocardiogr, 2016; 29, 1207-16. doi: 10.1016/j.echo.2016.09.001 [16] Zheng X, Zhang R, Liu X, et al. Association between cumulative exposure to ideal cardiovascular health and arterial stiffness. Atherosclerosis, 2017; 260, 56-62. doi: 10.1016/j.atherosclerosis.2017.03.018 [17] Yan N, Zhou Y, Wang Y, et al. Association of ideal cardiovascular health and brachial-ankle pulse wave velocity:a cross-sectional study in Northern China. J Stroke Cerebrovasc Dis, 2016; 25, 41-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.08.031 [18] Sturlaugsdottir R, Aspelund T, Bjornsdottir G, et al. Carotid atherosclerosis and cardiovascular health metrics in old subjects from the AGES-Reykjavik study. Atherosclerosis, 2015; 242, 65-70. doi: 10.1016/j.atherosclerosis.2015.06.043 [19] Guo L, Cheng L, He W, et al. Ideal Cardiovascular Health and Incidence of Carotid Plaque among Middle-Aged and Elderly Adults. J Stroke Cerebrovasc Dis, 2018; 27, 391-6. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.013 [20] Alman AC, Maahs DM, Rewers MJ, et al. Ideal cardiovascular health and the prevalence and progression of coronary artery calcification in adults with and without type 1 diabetes. Diabetes care, 2014; 37, 521-8. doi: 10.2337/dc13-0997 [21] Wang L, Li M, Zhao Z, et al. Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease:A Prospective Analysis. Am J Med, 2018; 131, 1515. [22] Guidelines for data processing and analysis of the International Physical Activity Questionnaire (IPAQ). https://sites.google.com/site/theipaq/scoring-protocol.2005. [23] Djaberi R, Schuijf JD, Jukema JW, et al. Increased carotid intima-media thickness as a predictor of the presence and extent of abnormal myocardial perfusion in type 2 diabetes. Diabetes Care, 2010; 33, 372-4. doi: 10.2337/dc09-1301 [24] Deng XR, Zhang YF, Wang TG, et al. Serum calcium level is associated with brachial-ankle pulse wave velocity in middle-aged and elderly Chinese. Biomed Environ Sci, 2014; 27, 594-600. http://cn.bing.com/academic/profile?id=6ef66a379462b6a292f10aa88c527ba4&encoded=0&v=paper_preview&mkt=zh-cn [25] Bi Y, Jiang Y, He J, et al. Status of cardiovascular health in Chinese adults. J Am Coll Cardiol, 2015; 65, 1013-25. doi: 10.1016/j.jacc.2014.12.044 [26] Shay CM, Ning H, Allen NB, et al. Status of cardiovascular health in US adults:prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2003-2008. Circulation, 2012; 125, 45-56. doi: 10.1161/CIRCULATIONAHA.111.035733 [27] Graciani A, Leon-Munoz LM, Guallar-Castillon P, et al. Cardiovascular health in a southern Mediterranean European country:a nationwide population-based study. Circ Cardiovasc Qual Outcomes, 2013; 6, 90-8. doi: 10.1161/CIRCOUTCOMES.112.967893 [28] Kanauchi M, Kanauchi K. Prevalence and distribution of ideal cardiovascular health metrics and association with metabolic syndrome in Japanese male workers. Int J Cardiol, 2016; 221, 428-9. doi: 10.1016/j.ijcard.2016.07.017 [29] Fernández-Alvira JM, Fuster V, Pocock S, et al. Predicting Subclinical Atherosclerosis in Low-Risk Individuals:Ideal Cardiovascular Health Score and Fuster-BEWAT Score. J Am Coll Cardiol, 2017; 70, 2463-73. doi: 10.1016/j.jacc.2017.09.032 [30] Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging, 2014; 7, 1025-38. doi: 10.1016/j.jcmg.2013.11.014 [31] Maeda Y, Inoguchi T, Etoh E, et al. Brachial-ankle pulse wave velocity predicts all-cause mortality and cardiovascular events in patients with diabetes:the Kyushu Prevention Study of Atherosclerosis. Diabetes Care, 2014; 37, 2383-90. doi: 10.2337/dc13-1886 [32] Geisel MH, Bauer M, Hennig F, et al. Comparison of coronary artery calcification, carotid intima-media thickness and ankle-brachial index for predicting 10-year incident cardiovascular events in the general population. Eur Heart J, 2017; 38, 1815-22. doi: 10.1093/eurheartj/ehx120 [33] Rundek T, Arif H, Bodenalbala B, et al. Carotid plaque, a subclinical precursor of vascular events:The Northern Manhattan Study. Neurology, 2008; 70, 1200-7. doi: 10.1212/01.wnl.0000303969.63165.34 [34] Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol, 2007; 2, 581-90. doi: 10.2215/CJN.03190906 [35] Cerasola G, Cottone S, Mule G. The progressive pathway of microalbuminuria:from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens, 2010; 28, 2357-69. http://cn.bing.com/academic/profile?id=57714a4fcc5e94e01ef19463dfc358f6&encoded=0&v=paper_preview&mkt=zh-cn [36] Karmali KN, Lloyd-Jones DM. Adding a life-course perspective to cardiovascular-risk communication. Nat Rev Cardiol, 2013; 10, 111-5. doi: 10.1038/nrcardio.2012.185 [37] Hwang SJ, Onuma O, Massaro JM, et al. Maintenance of Ideal Cardiovascular Health and Coronary Artery Calcium Progression in Low-Risk Men and Women in the Framingham Heart Study. Circ Cardiovasc Imaging, 2018; 11, e006209. http://cn.bing.com/academic/profile?id=8faa9611a9cf6a4b962f84fdba9e2a31&encoded=0&v=paper_preview&mkt=zh-cn [38] Zhang Y, Fang X, Hua Y, et al. Carotid Artery Plaques, Carotid Intima-Media Thickness, and Risk of Cardiovascular Events and All-Cause Death in Older Adults:A 5-Year Prospective, Community-Based Study. Angiology, 2018; 69, 120-9. doi: 10.1177/0003319717716842 [39] Laitinen TT, Pahkala K, Magnussen CG, et al. Lifetime measures of ideal cardiovascular health and their association with subclinical atherosclerosis:The Cardiovascular Risk in Young Finns Study. Int J Cardiol, 2015; 185, 186-91. doi: 10.1016/j.ijcard.2015.03.051 [40] Loria CM, Liu K, Lewis CE, et al. Early adult risk factor levels and subsequent coronary artery calcification:the CARDIA Study. J Am Coll Cardiol, 2007; 49, 2013-20. doi: 10.1016/j.jacc.2007.03.009 [41] McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors:Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol, 2015; 66, 1643-53. doi: 10.1016/j.jacc.2015.08.035